These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 310708)

  • 1. Effect of hapten plus antihapten-tumor serum treatment on established rat fibrosarcoma.
    Arai K; Spencer JS; Sohn M; Wallace HW
    Cancer Res; 1979 Jan; 39(1):6-16. PubMed ID: 310708
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of local immunotherapy of syngeneic rat fibrosarcoma with hapten and antihapten-tumor serum upon nonlocally treated tumor.
    Arai K; Wallace HW
    Cancer Res; 1979 Sep; 39(9):3638-43. PubMed ID: 314334
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of anti-hapten serum on hapten-treated rat tumor.
    Wallace HW; Arai K
    Surg Forum; 1978; 29():126-8. PubMed ID: 401112
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival of tumor allografts in rats treated with antithymocyte serum.
    Abandowitz HM; Basrur PK
    Z Naturforsch C; 1973; 28(9):631-2. PubMed ID: 4272308
    [No Abstract]   [Full Text] [Related]  

  • 5. Regression of untreated tumor following immunotherapy of primary tumor in rats.
    Arai K; Wallace HW; Blakemore WS
    Surg Forum; 1973; 24():117-8. PubMed ID: 4805961
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of homocytotropic antibody formation in the rat. VII. Carrier functions in the anti-hapten homocytotropic antibody response.
    Tada T; Okumura K; Taniguchi M
    J Immunol; 1972 Jun; 108(6):1535-41. PubMed ID: 4113175
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data.
    Baxter LT; Yuan F; Jain RK
    Cancer Res; 1992 Oct; 52(20):5838-44. PubMed ID: 1394212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haptenic activity of L-phenylalanine mustard.
    Arai K; Wallace HW; Blakemore WS
    Cancer Res; 1973 Aug; 33(8):1905-13. PubMed ID: 4198384
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of irradiated immune lymphoid cells for immunotherapy of primary tumors in rats.
    Alexander P; Delorme EJ
    Isr J Med Sci; 1971 Jan; 7(1):239-45. PubMed ID: 4395980
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of active and passive immunization and chemotherapy to transplantation of methylcholanthrene-induced tumor in WKA rats.
    Gotoda E; Sendo F; Hosokawa M; Kodama T; Kobayashi H
    Cancer Res; 1974 Aug; 34(8):1947-51. PubMed ID: 4842248
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies.
    Ward EC; Iglehart JD; Weinhold KJ; Bolognesi DP
    J Natl Cancer Inst; 1982 Aug; 69(2):509-15. PubMed ID: 6955550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of cancer with L-phenylalanine mustard as a hapten.
    Arai K; Wallace HW; Blakemore WS
    Cancer Res; 1973 Aug; 33(8):1914-20. PubMed ID: 4720800
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T; Bertera S; Chang AE; Shu S
    J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Augmentation of specific anti-tumor immunity by immunization with xenogenized tumor cells and its application to the experimental cancer treatment (author's transl)].
    Okayasu T
    Hokkaido Igaku Zasshi; 1981 Nov; 56(6):615-22. PubMed ID: 7338338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of polyclonal antibodies to the Ah receptor prepared by immunization with a synthetic peptide hapten.
    Poland A; Glover E; Bradfield CA
    Mol Pharmacol; 1991 Jan; 39(1):20-6. PubMed ID: 1846218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy of malignant tumors with subpopulations of T lymphocytes].
    Fernández-Cruz E
    Rev Esp Oncol; 1982; 29(4):701-10. PubMed ID: 6242320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on purification of antibodies against tumor-specific antigens.
    Park MM
    Pahlavi Med J; 1978 Jan; 9(1):1-26. PubMed ID: 652378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of the immune system in regression of a rat Mc7 sarcoma by hyperthermia.
    Shah SA
    Cancer Res; 1981 May; 41(5):1742-7. PubMed ID: 7214341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target.
    Moolten FL; Capparell NJ; Cooperband SR
    J Natl Cancer Inst; 1972 Oct; 49(4):1057-62. PubMed ID: 4343471
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
    Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.